Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


 
Cancer stem cells the target in new clinical trial
By admin at 2013-07-03 22:47
Cancer stem cells the target in new clinical trial

Breast cancer often returns as chemotherapyterm is designed to target the tumor but not the cancer stem cells that are often the root of the disease.


It is this focus that drives a new clinical trial open now at Michigan Comprehensive Cancer Center and two more sites. Reparixin will be used in combination with standard chemotherapy.



"This is one of only a few trials testing stem cell directed therapies in combination with chemotherapy in breast cancer. Combining chemotherapy with stem cell therapy has the potential to lengthen remissions for women with advanced breast cancer," says principal investigator Anne Schott, M.D., associate professor of internal medicine at the University of Michigan.


Cancer stem cells are the small number of cells within a tumor that fuel its growth and spread.


The phase Ib study will test reparixin, which is taken orally, along with the chemotherapy drug paclitaxel in women with HER2-negative metastaticterm breast cancer. The study is primarily intended to test how patients tolerate this drug combination, but researchers will also look at how reparixin appears to be impacting markers for cancer stem cells and signs of inflammation. The study will also look at how effective this treatment combination is at controlling the cancer and impacting survival.


The clinical trial stems from laboratory research at U-M that identified a receptor called CXCR1 on the cancer stem cells that triggers growth of stem cells in response to inflammation and tissue damage. Adding reparixin to chemotherapy in laboratory studies specifically targeted and killed breast cancer stem cells by blocking CXCR1.


Mice treated with reparixin or the combination of reparixin and chemotherapy had dramatically fewer cancer stem cells than those treated with chemotherapy alone. In addition, reparixin-treated mice developed significantly fewer metastases than mice treated with chemotherapy alone.


The study is sponsored by Dompe S.p.A. For more information about this trial, "Phase Ib pilot study to evaluate reparixin in combination with chemotherapy with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC)," call the U-M Cancer AnswerLine at 800-865-1125.


4678 reads

 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate





All times are GMT -5. The time now is 07:30 AM.